Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03581370 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients with Ventilator Associated-pneumonia

Study acronym: CEFTOREA
StatusUnknown
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 25, 2024 (before its estimated February 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Primary and study completion dates: Feb 2023 to Feb 2025 Site contact updatedv6 Show 1 more changeShow less
    • Site contact updated
  3. Re-verified, no change to tracked fieldsv5
  4. Primary and study completion dates: Jul 2021 to Feb 2023 Eligibility criteria revisedv4 Show 1 more changeShow less
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  5. Study title shortened, about 9 wordsv3 See this version in full on ClinicalTrials.gov ↗
  6. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jul 2018 to Sep 20, 2018 · Secondary endpoints: 11 to 9 · Site details revisedv2 Show 3 more changesShow less
    • Start date changed from estimate of Jul 2018 to Sep 20, 2018
    • Secondary endpoints: 11 to 9
    • Site details revised

    See this version in full on ClinicalTrials.gov ↗

  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main objective of this study is to compare the median exposures at pharmacokinetic equilibrium of the two modalities of administration: 4-hours infusion of ceftolozane-tazobactam at a dosage of 2 gram three times a day vs 1-hour infusion of 2 gram three times a day.
Trial Details
NCT Number NCT03581370
Lead Sponsor University Hospital, Toulouse
Conditions Ventilator-associated Pneumonia
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov